We started a phase II / III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage Alzheimer’s disease. It involves a change in the therapeutic target hitherto chosen: the amyloid protein
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
This study could improve the efficacy and safety of the products being evaluated to try…
We have reached the first position, in December 2019, in the international inclusion of patients…
Grifols has reported to the press the positive result of the AMBAR trial in patients…
On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial…
Neurology and Neuropsychology team specializes in the evaluation of biomarkers and the early diagnosis of…
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
© 2022–2026 - UDIC - Unitat d'Investigació Clínica, SL · Soporte técnico
No dude en contactarnos
(+34) 931 751 575
(+34) 935 656 000 ext 1756
(+34) 651 891 344
info@udic.es
